Ovid Therapeutics Stock: Risk-Adjusted Valuation Shows Deep Discount Despite 700% Rally

Ovid (OVID) Buy thesis: undervalued despite 700% surge, $193M cash runway to 2029, epilepsy & schizophrenia pipeline catalysts. See more here.

Read on WOBR AI →